Steroid-Induced Depression, Can't Stop the Steroid
High-dose prednisone is the most likely cause of her new depression, and it's also the only thing currently holding a kidney-threatening flare of lupus nephritis in check — tapering it isn't an option, so the depression has to be treated around it.
A.F., a 34-year-old graduate student in public health, was diagnosed with lupus nephritis eight weeks ago after presenting with significant proteinuria and a rising creatinine, and has been on prednisone 60mg daily since diagnosis as induction therapy alongside mycophenolate, with her rheumatology team explicit that this dose cannot be safely tapered until her kidney function and proteinuria show sustained improvement. She has no psychiatric history before this illness and no other chronic illness beyond the newly diagnosed lupus itself.
Roughly three weeks into high-dose steroid therapy, she began describing a persistent low mood, tearfulness, poor sleep, and a loss of interest in coursework she had previously found engaging — a distinct change from how she describes herself before starting prednisone, and one that has continued and worsened over the five weeks since. Her psychiatric evaluation specifically screened for steroid-induced mania or psychosis, given that high-dose corticosteroids can produce either mood direction, and found no evidence of elevated or irritable mood, grandiosity, or psychotic symptoms — her presentation is consistently and exclusively depressive.
The genuine complication is that the most likely cause of her depression is also the treatment actively preventing kidney failure. Corticosteroid-induced psychiatric symptoms are often dose-related and can improve with taper, but her rheumatology team has been clear that reducing her prednisone now risks a flare severe enough to threaten permanent renal damage — tapering the presumed cause is not an available option regardless of how confident the causal link is. That leaves treating the depression pharmacologically while the steroid dose stays fixed, which raises a second, more specific problem: prednisone is partly metabolized through CYP3A4, and an SSRI with meaningful inhibitory effects on that pathway could raise her effective steroid exposure in a way that complicates her rheumatologist's own dosing calculations.
At the combined rheumatology-psychiatry consultation
I need to be direct that tapering prednisone is not something we can offer as a treatment for her mood right now — her proteinuria hasn't shown the sustained improvement we need to see before reducing the dose, and a flare at this stage carries a real risk of permanent renal damage. Whatever the team decides for her depression has to work around a fixed steroid dose, not toward reducing it.
That constraint doesn't change how we'd treat her depression, which is reassuring in a specific way — corticosteroid-induced depressive symptoms generally respond to standard antidepressant treatment even when the steroid itself can't be reduced, unlike steroid-induced mania or psychosis, which are managed differently. Her presentation being cleanly depressive, without mixed or psychotic features, is actually the more treatable version of this problem to have.
The one thing I'd steer away from specifically is fluvoxamine or any other SSRI with meaningful CYP3A4 inhibitory activity — prednisone's own metabolism runs partly through that pathway, and raising her effective steroid exposure unintentionally would complicate exactly the dosing precision her rheumatologist is managing carefully. Sertraline or escitalopram, both with comparatively minimal CYP3A4 interaction, treat the depression without adding a second variable to her steroid dosing.
Sertraline 50mg was started, chosen specifically to avoid interfering with prednisone's CYP3A4-dependent metabolism, with the steroid regimen continued unchanged per rheumatology's assessment of her renal disease activity.
The team documented explicitly that her depression is being treated as steroid-associated but not steroid-reversible under current circumstances — a distinction that matters for how her care is coordinated going forward, since improvement is expected to come from the antidepressant rather than from any change to the corticosteroid regimen driving both her renal treatment and, most likely, her mood.